96.71
-0.78
(-0.80%)
May 17 - Close
FRA
real-time data -
Disclaimer
Currency in EUR
| Range | 96.42 - 97.78 |
| 52 week | 73.43 - 99.73 |
| Open | 97.78 |
| Vol. | 1,893.00 |
| Mkt cap | 17.24B |
| P/E | 18.76 |
| Div/yield | 1.10/1.14 |
| EPS | 5.15 |
| Shares | 178.31M |
| Beta | - |
| Inst. own | - |
Events
Aug 6, 2013
Q2 2013 Fresenius SE & Co KGaA Earnings Release (IFRS)
Aug 2, 2013
Q2 2013 Fresenius SE & Co KGaA Earnings Release (US GAAP)
Jul 30, 2013
Q2 2013 Fresenius SE & Co KGaA Earnings Conference Call
May 22, 2013
Fresenius SE & Co KGaA at Barclays High Yield and Syndicated Loan Conference
- 5:50PM GMT+2 -
May 14, 2013
Fresenius SE & Co KGaA at Deutsche Bank German, Swiss & Austrian Conference
May 8, 2013
Q1 2013 Fresenius SE & Co KGaA Earnings Release (IFRS)
May 6, 2013
Q1 2013 Fresenius SE & Co KGaA Earnings Release (US GAAP)
Mar 19, 2013
Full Year 2012 Fresenius SE & Co KGaA Earnings Release (US GAAP and IFRS)
Mar 14, 2013
Fresenius SE & Co KGaA at Bank of America Merrill Lynch European High Yield Healthcare Conference
Mar 6, 2013
Fresenius SE & Co KGaA at Goldman Sachs Leveraged Finance Healthcare Conference
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 7.61% | 8.88% |
| Operating margin | 13.99% | 15.31% |
| EBITD margin | - | 20.18% |
| Return on average assets | 4.83% | 6.05% |
| Return on average equity | 11.01% | 13.08% |
| Employees | 171,764 | - |
| Carbon Disclosure Rating | - | 22/100 |
Address
Else-Kroener-Str. 1
BAD HOMBURG, 61352
Germany
+49-6172-6080 (Phone)
+49-617-26082294 (Fax)
BAD HOMBURG, 61352
Germany
+49-6172-6080 (Phone)
+49-617-26082294 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Fresenius SE & Co KGaA is a Germany-based holding company of the Fresenius Group, operating in the healthcare sector, which offers products and services for dialysis, hospitals and outpatient medical care. The Group operates five business segments: Fresenius Medical Care; Fresenius Kabi; Fresenius Helios; Fresenius Vamed, and Corporate/Other, which mainly comprises the holding functions of the Company and Fresenius Netcare GmbH. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of generic drugs (IV drugs), infusion therapies, clinical nutrition, and related medical services. The Fresenius Helios segment is a hospital operator and operates 65 clinics, 45 acute care hospitals, 30 medical care centers and 10 nursing homes. The Fresenius Vamed segment is engaged in international projects and services for hospitals and other health care facilities.
Officers and directors
| Gerd Krick | Chairman of the Supervisory Board | |
| Ulf Mark Schneider | Chairman of the Management Board | |
| Gerhard Rupprecht | Deputy Chairman of the Supervisory Board | |
| Niko Stumpfoegger | Deputy Chairman of the Supervisory Board, Employee Representative | |
| Stephan Sturm | Chief Financial Officer, Member of the Management Board | |
| Birgit Grund | Senior Vice President of Investor Relations | |
| Juergen Goetz | Chief Legal and Compliance Officer, Labor Relations Director, Member of the Management Board | |
| Rainer Baule | Member of the Management Board | |
| Francesco De Meo | Member of the Management Board, Chief Executive Officer of Fresenius Helios | |
| Ben J. Lipps | Member of the Management Board |